BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9217027)

  • 1. An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.
    Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Wilhelm Schildberg F; Heiss MM
    Cancer; 1997 Jul; 80(2):179-87. PubMed ID: 9217027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
    Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Schildberg FW; Heiss MM
    Clin Exp Metastasis; 1998 Jan; 16(1):62-73. PubMed ID: 9502078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
    J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.
    Allgayer H; Babic R; Gruetzner KU; Tarabichi A; Schildberg FW; Heiss MM
    J Clin Oncol; 2000 Jun; 18(11):2201-9. PubMed ID: 10829039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
    Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
    Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer.
    Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
    Eur J Surg Oncol; 1996 Feb; 22(1):74-7. PubMed ID: 8846873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
    Allgayer H; Babic R; Beyer BC; Grützner KU; Tarabichi A; Schildberg FW; Heiss MM
    Oncology; 1998; 55(2):152-60. PubMed ID: 9499190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
    Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
    Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
    Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological significance of cathepsin D expression in gastric adenocarcinoma.
    Ikeguchi M; Fukuda K; Oka S; Yamaguchi K; Hisamitsu K; Tsujitani S; Sakatani T; Ueda T; Kaibara N
    Oncology; 2001; 61(1):71-8. PubMed ID: 11474252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
    Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao E; Han D; Yu Z; Fan E; Li Y; Zhou Z
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Nov; 16(11):599-602. PubMed ID: 15515548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteine and serine proteases in gastric cancer.
    Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
    Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
    Kute TE; Grøndahl-Hansen J; Shao SM; Long R; Russell G; Brünner N
    Breast Cancer Res Treat; 1998 Jan; 47(1):9-16. PubMed ID: 9493971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
    Heiss MM; Simon EH; Beyer BC; Gruetzner KU; Tarabichi A; Babic R; Schildberg FW; Allgayer H
    J Clin Oncol; 2002 Apr; 20(8):2005-16. PubMed ID: 11956259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.